828 WINTER STREET, WALTHAM, MA
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Xilio Therapeutics Begins Phase 2 Trial for Efarindodekin Alfa, Achieves $17.5M Milestone with Gilead
Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
Shareholder votes
Changes in Board, Management or Compensation
Announces Pricing of $50.0 Million Public Offering
Xilio Announces Phase 2 Results for Vilastobart in Colorectal Cancer Treatment
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Correspondence